Lanreotide promotes apoptosis and is not radioprotective in GH3 cells

Endocrine-Related Cancer

Volumn 16, Issue 3, 2009, Pages 1045-1055

  Ning, Shoucheng ^a   Knox, Susan J ^a   Harsh, Griffith R ^a   Culler, Michael D ^b   Katznelson, Laurence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN GH3; CELL SURVIVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; GROWTH HORMONE SECRETING ADENOMA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RADIATION DOSE; RADIATION PROTECTION; RADIOSENSITIVITY; RAT; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA RAYS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; MALE; MICE; MICE, NUDE; PEPTIDES, CYCLIC; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RATS; SOMATOSTATIN; SOMATOTROPHS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72749119236     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0003     Document Type: Article

References (40)

1. Arnold R, Wied M & Behr TH 2002 Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opinion on Pharmacotherapy 3 643-656. (Pubitemid 34649694)
2. Ashkenazi A & Dixit VM 1998 Death receptors: signaling and modulation. Science 281 1305-1308.
3. Baldysiak-Figiel A, Jong-Hesse YD, Lang GK & Lang GE 2005 Octreotide inhibits growth factor-induced and basal proliferation of lens epithelial cells in vitro. Journal of Cataract and Refractive Surgery 31 1059-1064. (Pubitemid 40840152)
4. Ben-Shlomo A & Melmed S 2001 Acromegaly. Endocrinology and Metabolism Clinics of North America 30 565-583 vi.
5. Bombardieri E, Crippa F, Cataldo I, Chiti A, Seregni E, Soresi E, Boffi R, Invernizzi G & Buraggi GL 1995 Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. European Journal of Cancer 31A 184-188.
6. Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, Conte-Devolx B, Réqis J, Dufour H, Brue T et al. 2005 Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. Journal of Clinical Endocrinology and Metabolism 90 4483-4488. (Pubitemid 41159330)
7. Cheung NW & Boyages SC 1995 Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 136 4174-4181.
8. Danila DC, Zhang X, Zhou Y, Dickersin GR, Fletcher JA, Hedley-Whyte ET, Selig MK, Johnson SR & Klibanski A 2000 A human pituitary tumor-derived folliculostellate cell line. Journal of Clinical Endocrinology and Metabolism 85 1180-1187. (Pubitemid 32269369)
9. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD & Klibanski A 2001 Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Journal of Clinical Endocrinology and Metabolism 86 2976-2981. (Pubitemid 32673451)
10. Dasgupta P, Singh AT & Mukherjee R 1999 Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Biochemical and Biophysical Research Communications 259 379-384. (Pubitemid 29281241)
11. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V & Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine 73 233-240.
12. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 90 4465-4473. (Pubitemid 41159328)
13. Garcia PD & Myers RM 1994 Pituitary cell line GH3 expresses two somatostatin receptor subtypes that inhibit adenylyl cyclase: functional expression of rat somato-statin receptor subtypes 1 and 2 in human embryonic kidney 293 cells. Molecular Pharmacology 45 402-409. (Pubitemid 24094928)
14. Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C & Bousquet C 2003 Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. PNAS 100 155-160. (Pubitemid 36078044)
15. Hejna M, Schmidinger M & Raderer M 2002 The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Annals of Oncology 13 653-668.
16. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S et al. 2006 Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology 155 371-379. (Pubitemid 44269455)
17. Ingle JN, Kardinal CG, Suman VJ, Krook JE & Hatfield AK 1996 Octreotide as first-line treatment for women with metastatic breast cancer. Investigational New Drugs 14 235-237. (Pubitemid 26340695)
18. Jenkins PJ, Bates P, Carson MN, Stewart PM & Wass JA 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 91 1239-1245.
19. Kanashiro CA, Schally AV, Nagy A & Halmos G 2005 Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. International Journal of Oncology 27 169-174.
20. Katznelson L 2005 Diagnosis and treatment of acromegaly. Growth Hormone and IGF Research 15 S31-S35.
21. Kim DW, Huamani J, Fu A & Hallahan DE 2006 Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. International Journal of Radiation Oncology, Biology, Physics 64 38-46. (Pubitemid 41831207)
22. Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C et al. 2004 Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clinical Cancer Research 10 4398-4405. (Pubitemid 38878880)
23. Lamberts SW, van der Lely AJ, de Herder WW & Hofland LJ 1996 Octreotide. New England Journal of Medicine 334 246-254.
24. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J & Wellis G 2000 Octreotide may act as a radioprotective agent in acromegaly. Journal of Clinical Endocrinology and Metabolism 85 1287-1289. (Pubitemid 32269387)
25. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani G, Cellai I, Ammannati F, Spada A et al. 2005 Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormonesecreting and nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 90 6156-6161. (Pubitemid 41613670)
26. Melen-Mucha G, Balcerczak E, Mucha S, Panczyk M, Lipa S & Mirowski M 2004 Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation. Neoplasma 51 319-324. (Pubitemid 38915551)
27. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A 1995 Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 80 1386-1392.
28. Pelicci G, Pagliacci MC, Lanfrancone L, Pelicci PG, Grignani F & Nicoletti I 1990 Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro. Journal of Endocrinological Investigation 13 657-662. (Pubitemid 20359924)
29. Pollock BE, Nippoldt TB, Stafford SL, Foote RL & Abboud CF 2002 Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. Journal of Neurosurgery 97 525-530.
30. Prevost G, Bourgeois Y, Mormont C, Lerrant Y, Veber N, Poupon MF et al. 1994 Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6. Life Sciences 55 155-162. (Pubitemid 24187112)
31. Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, Kornek GV, Vorbeck F, Hejna MHL, Virgolini I et al. 1999 Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. British Journal of Cancer 79 535-537. (Pubitemid 29046232)
32. Rezacova M, Cap J, Vokurkova D, Lukasova E, Vavrova J, Cerman J, Masin V & Mazankova N 2008 Effect of somatostatin on repair of ionizing radiation-induced DNA damage in pituitary adenoma cells GH3. Physiological Research 57 225-235.
33. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH & Peter ME 1998 Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal 17 1675-1687. (Pubitemid 28119121)
34. Sharma K & Srikant CB 1998 G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification. Biochemical and Biophysical Research Communications 242 134-140. (Pubitemid 28412391)
35. Sharma K, Patel YC & Srikant CB 1996 Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Molecular Endocrinology 10 1688-1696. (Pubitemid 26408756)
36. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD & Melmed S 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. Journal of Clinical Investigation 99 789-798. (Pubitemid 27097683)
37. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK 2006 Octreotide, a somatostatin analogue, mediates its anti-proliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 66 1576-1582. (Pubitemid 43259940)
38. Vainas IG 2001 Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 47 109-126. (Pubitemid 32238647)
39. Weckbecker G, Liu R, Tolcsvai L & Bruns C 1992 Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Research 52 4973-4978.
40. Zeytin FN, Gick GG, Brazeau P, Ling N, McLaughlin M & Bancroft C 1984 Growth hormone (GH)-releasing factor does not regulate GH release or GH mRNA levels in GH3 cells. Endocrinology 114 2054-2059. (Pubitemid 14120255)